Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease

Overview

Journal Front Pharmacol

Date 2021 May 31

PMID 34054542

Citations 22

Authors

Annunziata Nusca

Dario Tuccinardi

Silvia Pieralice

Sara Giannone

Myriam Carpenito

Lavinia Monte

Mikiko Watanabe

Ilaria Cavallari

Ernesto Maddaloni

Gian Paolo Ussia

Silvia Manfrini

Francesco Grigioni

Affiliations

Soon will be listed here.

Abstract

In type 2 diabetes, anti-thrombotic management is challenging, and current anti-platelet agents have demonstrated reduced efficacy. Old and new anti-diabetic drugs exhibited-besides lowering blood glucose levels-direct and indirect effects on platelet function and on thrombotic milieu, eventually conditioning cardiovascular outcomes. The present review summarizes existing evidence on the effects of glucose-lowering agents on platelet properties, addressing pre-clinical and clinical research, as well as drug-drug interactions with anti-platelet agents. We aimed at expanding clinicians' understanding by highlighting new opportunities for an optimal management of patients with diabetes and cardiovascular disease. We suggest how an improvement of the thrombotic risk in this large population of patients may be achieved by a careful and tailored combination of anti-diabetic and anti-platelet therapies.

Citing Articles

Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes.

Piccirillo F, Lanciotti M, Nusca A, Frau L, Spano A, Liporace P Int J Mol Sci. 2025; 26(5).

PMID: 40076724 PMC: 11899902. DOI: 10.3390/ijms26052103.

Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies.

Siam N, Snigdha N, Tabasumma N, Parvin I Rev Cardiovasc Med. 2025; 25(12):436.

PMID: 39742220 PMC: 11683709. DOI: 10.31083/j.rcm2512436.

Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?.

Kumbhar P, Chavan R, Darekar S, Kolekar K, Sequeira A, Vishwas S Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39520555 DOI: 10.1007/s00210-024-03578-7.

Concomitant Use of Oral Anticoagulants with Oral Dipeptidyl Peptidase-4 Inhibitors and Serious Bleeding Events.

Pham Nguyen T, Leonard C, Brensinger C, Bilker W, Chung S, Horn J Clin Pharmacol Ther. 2024; .

PMID: 39262110 PMC: 11893511. DOI: 10.1002/cpt.3442.

Contrast-induced acute kidney injury: a review of definition, pathogenesis, risk factors, prevention and treatment.

Li Y, Wang J BMC Nephrol. 2024; 25(1):140.

PMID: 38649939 PMC: 11034108. DOI: 10.1186/s12882-024-03570-6.

References

Barale C, Frascaroli C, Cavalot F, Russo I . Hypercholesterolemia impairs the Glucagon-like peptide 1 action on platelets: Effects of a lipid-lowering treatment with simvastatin. Thromb Res. 2019; 180:74-85. DOI: 10.1016/j.thromres.2019.06.010. View

Angiolillo D, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass T . Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007; 49(14):1505-16. DOI: 10.1016/j.jacc.2006.11.044. View

Gupta A, Verma A, Kailashiya J, Singh S, Kumar N . Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. Platelets. 2012; 23(8):565-70. DOI: 10.3109/09537104.2012.721907. View

Sidhu J, Cowan D, Kaski J . The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol. 2003; 42(10):1757-63. DOI: 10.1016/j.jacc.2003.04.001. View

Chokesuwattanaskul W, Yaqub Y, Suarez J, Simoni J, Simoni G, Nugent K . Effect of pioglitazone on platelet aggregation in a healthy cohort. Cardiology. 2010; 116(4):253-6. DOI: 10.1159/000318024. View

Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290(4):486-94. DOI: 10.1001/jama.290.4.486. View

Lamanna C, Monami M, Marchionni N, Mannucci E . Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011; 13(3):221-8. DOI: 10.1111/j.1463-1326.2010.01349.x. View

Gobel F, Norstrom L, Nelson R, Jorgensen C, Wang Y . The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation. 1978; 57(3):549-56. DOI: 10.1161/01.cir.57.3.549. View

Maruthur N, Tseng E, Hutfless S, Wilson L, Suarez-Cuervo C, Berger Z . Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016; 164(11):740-51. DOI: 10.7326/M15-2650. View

10.

Tremoli E, Ghiselli G, Maderna P, Colli S, Sirtori C . Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits. Atherosclerosis. 1982; 41(1):53-60. DOI: 10.1016/0021-9150(82)90069-7. View

11.

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

12.

Rivas Rios J, Franchi F, Rollini F, Angiolillo D . Diabetes and antiplatelet therapy: from bench to bedside. Cardiovasc Diagn Ther. 2018; 8(5):594-609. PMC: 6232350. DOI: 10.21037/cdt.2018.05.09. View

13.

Chilton R, Tikkanen I, Cannon C, Crowe S, Woerle H, Broedl U . Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 17(12):1180-93. PMC: 5057299. DOI: 10.1111/dom.12572. View

14.

Kahal H, Aburima A, Ungvari T, Rigby A, Coady A, Vince R . The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. BMC Endocr Disord. 2015; 15:14. PMC: 4389314. DOI: 10.1186/s12902-015-0005-6. View

15.

Almutairi M, Al Batran R, Ussher J . Glucagon-like peptide-1 receptor action in the vasculature. Peptides. 2018; 111:26-32. DOI: 10.1016/j.peptides.2018.09.002. View

16.

Aroor A, Das N, Carpenter A, Habibi J, Jia G, Ramirez-Perez F . Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc Diabetol. 2018; 17(1):108. PMC: 6065158. DOI: 10.1186/s12933-018-0750-8. View

17.

Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher A . Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999; 399(6736):601-5. DOI: 10.1038/21224. View

18.

Violi F, De Mattia G, Alessandri C, Perrone A, Vezza E . The effects of gliclazide on platelet function in patients with diabetes mellitus. Curr Med Res Opin. 1982; 8(3):200-3. DOI: 10.1185/03007998209112384. View

19.

Konya H, Hasegawa Y, Hamaguchi T, Satani K, Umehara A, Katsuno T . Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. Metabolism. 2010; 59(9):1294-9. DOI: 10.1016/j.metabol.2009.12.004. View

20.

White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327-35. DOI: 10.1056/NEJMoa1305889. View